Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P) Meeting Abstract

  

Authors:	McConkey, D. J.; Choi, W.; Halabi, S.; Luo, B.; Al-Ahmadie, H. A.; Rosenberg, J. E.; Mountain, J.; Regazzi, A. M.; Fong, M.; Iyer, G.; Van Allen, E. M.; Mouw, K. W.; Wen, Y.; McCart, L.; Ballman, K. V.; Beltran, H.; Morris, M. J.
Abstract Title:	Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P)
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680301382
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.4562
Notes:	Meeting Abstract: 4562 -- Meeting also held virtually -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201480